The myeloperoxidase -463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls.
Genetic polymorphism of human myeloperoxidase (MPO) -463G/A has been implicated to alter the risk of coronary artery disease (CAD), but the results are controversial. To improve the reliability of the conflicting results, we conducted a meta-analysis of studies relating the MPO -463G/A polymorphism with the risk of CAD. Two investigators independently searched the MEDLINE, EMBASE and Cochrane Library up to June, 2012. Summary odds ratios (OR) and 95% confidence interval (CI) for the MPO -463G/A polymorphism and CAD risk were calculated, and potential sources of heterogeneity and publication bias were explored. Statistical analysis was performed with the software program of Stata 9.0. 5 case-control studies were finally identified for analyses, involving 1938 cases with CAD and 1990 controls. We found that the MPO -463G/A polymorphism has no significant association with overall CAD risk (G/G vs A/A: OR=0.595, 95%CI=0.298-1.188, P=0.141; G/G vs G/A+A/A: OR=0.886, 95%CI=0.779-1.008, P=0.066; G/G+G/A vs A/A: OR=0.611, 95%CI=0.334-1.119, P=0.111; OR=0.886, 95%CI=0.779-1.008, P=0.066; G vs A: OR=0.843, 95%CI=0.675-1.053, P=0.133). The heterogeneity test showed that there were significant differences between individual studies in additive, recessive and allelic genetic models (P=0.008, P=0.021, P=0.019, respectively); further analyses revealed that age and sex possibly account for the heterogeneity. Our meta-analysis demonstrated the evidence that there was no significant association between the MPO -463G/A polymorphism and the risk of CAD; larger and well-designed multicenter studies are needed to confirm our results.